Achievement of Vancomycin Therapeutic Goals in Critically Ill Patients: Early Individualization May Be Beneficial

Table 1

Demographic and pharmacokinetic parameters in two groups of patients.

	Measures	Group 1	Group 2	Sig. (2-tailed)
		Mean ± SD	Mean ± SD
	Number of patients	10	10	—
Baseline	Sex (male/female)	8/2	8/2	0.61
	Age (year)	48.5 ± 18.3	47.7 ± 20.9	0.93
	Body weight (kg)	66.0 ± 12.1	73.0 ± 12.2	0.24
	Height (cm)	170.1 ± 9.1	171.5 ± 13.9	0.78
	APACHE score	10.6 ± 1.7	13.3 ± 1.4	0.31
	eGFR (mL/min)	99.8 ± 49.8	112.4 ± 45.7	0.58
	Number of patients	8	10	—
Steady state	eGFR (mL/min)	111.1 ± 57.2	113.2 ± 45.9	0.93
	Total dose (mg/kg)	44.9 ± 3.8	49.4 ± 13.1	0.33
	Trough (mg/L)	14.4 ± 4.3	19.4 ± 4.4	0.03
	Peak (mg/L)	28.1 ± 6.0	33.7 ± 6.7	0.07
	(L/kg)	0.65 ± 0.12	0.68 ± 0.10	0.61
	Clvanco (mL/min)	45.1 ± 54.8	79.3 ± 53.7	0.20
	AUC (mg⋅hr/L)	490.7 ± 101.0	665.9 ± 136.5	0.01

eGFR: estimated glomerular filtration rate, AUC: area under the curve, Cl: clearance, : volume of distribution, and Vanco: vancomycin.